Conference Call Participants
David Risinger – Leerink Partners LLC, Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Terence Flynn – Morgan Stanley, Research Division
Jiale Song – Jefferies LLC, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Patrick Dolezal – LifeSci Capital, LLC, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Cameron DeGuzman – Wolfe Research, LLC
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Hardik Parikh – JPMorgan Chase & Co, Research Division
Presentation
Operator
Good morning, and welcome to the Structure Therapeutics conference call. [Operator Instructions] Please be advised today’s conference is being recorded.
I would now like to turn the call over to Jen Robinson, Head of Investor Relations for Structure Therapeutics.
Jennifer Robinson
Thank you, and good morning. Earlier today, we issued a press release providing data updates from ACCG-2671, our oral small molecule dual amylin and calcitonin receptor agonist, and aleniglipron ACCESS open-label extension results. A copy of the press release and the presentation accompanying today’s call are available in the Investor Relations section of Structure Therapeutics’ website.
I would like to remind everyone that some of the statements we will make on this call and information presented in the slide deck may include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially. Please refer